User: Guest  Login
Title:

[Intravitreal injection of bevacizumab for exsudative AMD with occult or minimal classic choroidal neovascularisation (CNV)]

Document type:
Clinical Trial; English Abstract; Journal Article
Author(s):
Maier, M; Feucht, N; Haas, K; Fiore, B; Winkler von Mohrenfels, C; Clos, A; Löhmann, C
Abstract:
PURPOSE: Systemic anti-VEGF therapy with bevacizumab was effective in neovascular AMD in the SANA study. Intravitreal bevacizumab has the advantage that a high concentration can be achieved in the eye with a low dose. First clinical studies showed a good therapeutic effect. METHODS: In a clinical study 93 patients with occult or minimal classic CNV due to neovascular AMD were treated with intravitreal injections of Bevacizumab (1.25 mg). Before, 1, 3 and 6 months after treatment visual acuity, i...     »
Journal title abbreviation:
Klin Monatsbl Augenheilkd
Year:
2008
Journal volume:
225
Journal issue:
9
Pages contribution:
818-24
Language:
de
Fulltext / DOI:
doi:10.1055/s-2008-1027638
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/18759214
Print-ISSN:
0023-2165
TUM Institution:
Klinik und Poliklinik für Augenheilkunde
 BibTeX